X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (195) 195
Publication (17) 17
Dissertation (6) 6
Newspaper Article (5) 5
Book Review (4) 4
Book / eBook (3) 3
Conference Proceeding (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (131) 131
humans (125) 125
male (115) 115
female (110) 110
middle aged (109) 109
adult (96) 96
pharmacology & pharmacy (88) 88
pharmacokinetics (65) 65
aged (63) 63
area under curve (37) 37
adolescent (36) 36
double-blind method (27) 27
safety (27) 27
renal dialysis (26) 26
young adult (25) 25
half-life (24) 24
renal impairment (24) 24
research (23) 23
care and treatment (22) 22
hepatic impairment (22) 22
administration, oral (21) 21
antiviral agents - pharmacokinetics (20) 20
analysis (19) 19
dose-response relationship, drug (17) 17
drug therapy (17) 17
treatment outcome (17) 17
efficacy (16) 16
pharmacology/toxicology (16) 16
hemodialysis (15) 15
kidney diseases (15) 15
severity of illness index (15) 15
medicine & public health (14) 14
pharmacology (14) 14
studies (14) 14
therapy (14) 14
antiviral agents - adverse effects (13) 13
drug administration schedule (13) 13
drug dosages (13) 13
internal medicine (13) 13
metabolic clearance rate (13) 13
antiviral agents (12) 12
cross-over studies (12) 12
dosage and administration (12) 12
time factors (12) 12
aged, 80 and over (11) 11
antiviral agents - administration & dosage (11) 11
kidney failure, chronic - blood (11) 11
kidney failure, chronic - metabolism (11) 11
liver diseases - metabolism (11) 11
microbiology (11) 11
clinical trials (10) 10
health aspects (10) 10
hepatitis c, chronic - drug therapy (10) 10
hypertension (10) 10
hypertension - drug therapy (10) 10
kidney failure, chronic - therapy (10) 10
pharmacotherapy (10) 10
renal insufficiency - metabolism (10) 10
abridged index medicus (9) 9
antiviral agents - therapeutic use (9) 9
confidence intervals (9) 9
diagnosis (9) 9
hepatitis c virus (9) 9
infections (9) 9
kidney diseases - metabolism (9) 9
metabolism (9) 9
peripheral vascular disease (9) 9
usage (9) 9
case-control studies (8) 8
chronic kidney-disease (8) 8
disease (8) 8
drug therapy, combination (8) 8
hepacivirus - drug effects (8) 8
liver diseases (8) 8
metabolites (8) 8
patients (8) 8
viral nonstructural proteins - antagonists & inhibitors (8) 8
antihypertensive agents - therapeutic use (7) 7
combination (7) 7
diabetes (7) 7
diabetes mellitus, type 2 - drug therapy (7) 7
double-blind (7) 7
end-stage renal disease (7) 7
failure (7) 7
hcv (7) 7
hepatitis c (7) 7
impairment (7) 7
infection (7) 7
infectious diseases (7) 7
kidney failure (7) 7
liver-disease (7) 7
mortality (7) 7
pharmacodynamics (7) 7
protein binding (7) 7
ribavirin (7) 7
single (7) 7
special populations (7) 7
antihypertensive agents - adverse effects (6) 6
bioavailability (6) 6
blood pressure - drug effects (6) 6
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (2) 2
UTL at Downsview - May be requested (2) 2
Pontifical Inst. Mediaeval Studies - Library use only (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
UofT at Mississauga - Stacks (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
Victoria University E.J. Pratt - Storage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
ISSN 0264-410X, 03/2012, Volume 30, Issue 13, p. 2245
  Fifty healthy adult (18-55 years) and 48 elderly (>=65 years) volunteers were randomized to receive a candidateClostridium difficiletoxoid vaccine (2μg,... 
Studies | Immunization | Diarrhea | Vaccines
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 4, pp. 805 - 812
Background & Aims Paritaprevir, ombitasvir, and dasabuvir are direct-acting antivirals for treatment of chronic hepatitis C virus (HCV) infection. The aim of... 
Gastroenterology and Hepatology | Direct-acting antiviral agents | Ombitasvir | Chronic hepatitis C | Hepatic impairment | Ritonavir | Paritaprevir | Pharmacokinetics | Dasabuvir | ABT-450/R-OMBITASVIR | TRANSPORTER EXPRESSION | RIBAVIRIN | LIVER-DISEASE | GENOTYPE 1 | THERAPY | CIRRHOSIS | HCV | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | Humans | Middle Aged | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Carbamates - pharmacokinetics | Dose-Response Relationship, Drug | Uracil - administration & dosage | Ribavirin - administration & dosage | Ribavirin - pharmacokinetics | Female | Drug Therapy, Combination | Liver Function Tests | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Ritonavir - administration & dosage | Macrocyclic Compounds - pharmacokinetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatic Insufficiency - blood | Hepatitis C, Chronic - blood | Sulfonamides - pharmacokinetics | Ritonavir - pharmacokinetics | Anilides - administration & dosage | Macrocyclic Compounds - administration & dosage | Hepatic Insufficiency - etiology | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Antiviral agents | Safety and security measures | Hepatitis C virus | Hepatitis C | Index Medicus
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2016, Volume 11, Issue 6, pp. e0157335 - e0157335
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2/2017, Volume 56, Issue 2, pp. 153 - 163
The direct-acting antiviral agent (DAA) combination of ombitasvir and paritaprevir (administered with ritonavir) with (3D regimen) or without (2D regimen)... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | SERUM CREATININE | TRIAL | VIVO ANTIVIRAL ACTIVITY | IN-VITRO | ABT-450/R-OMBITASVIR | INTERFERON | TREATMENT-NAIVE | PHARMACOLOGY & PHARMACY | HCV | RESISTANCE PROFILE | RIBAVIRIN | Antiviral Agents - pharmacokinetics | Anilides - adverse effects | Humans | Middle Aged | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Carbamates - pharmacokinetics | Hepacivirus - metabolism | Ritonavir - adverse effects | Uracil - administration & dosage | Kidney Diseases - epidemiology | Female | Kidney Diseases - blood | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Hepacivirus - drug effects | Ritonavir - administration & dosage | Kidney Diseases - drug therapy | Macrocyclic Compounds - pharmacokinetics | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatitis C, Chronic - blood | Sulfonamides - pharmacokinetics | Ritonavir - pharmacokinetics | Uracil - adverse effects | Anilides - administration & dosage | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Care and treatment | Usage | Diagnosis | Hepatitis C virus | Ritonavir | Proteins | Survival analysis | Hepatitis | Comorbidity | Liver | Infections | Interferon | Family medical history | Kidney diseases | Drug dosages | Pharmaceuticals | Index Medicus
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 03/2018, Volume 62, Issue 3
Journal Article
Journal Article